A pharmaceutical composition which comprises a pharmaceutically acceptable carrier together with an in vivo fibrinolytic enzyme as defined herein wherein the catalytic site essential for fibrinolytic activity is blocked by a group which is removable by hydrolysis at a rate such that the pseudo-first order rate constant for hydrolysis is in the range 10-6 sec-1 to 10-3sec-1 in isotonic aqueous media at pH 7.4 at 37°C; is useful in the treatment of venous thrombosis.
一种药物组合物,它包括药学上可接受的载体和本文定义的体内
纤维蛋白溶解酶,其中
纤维蛋白溶解活性所必需的催化位点被一个基团阻断,该基团可通过
水解去除,
水解的假一阶速率常数在 10-6 秒-1 到 10-3 秒-1 之间,在 37°C pH 值为 7.4 的等渗
水介质中;该药物组合物可用于治疗静脉血栓。